CR CRSP CRISPR Therapeutics Loading... : Bullish and Bearish Analyst Opinions

The author dismisses the ARKK portfolio as an avoid list without taking a directional position on any individual ticker.

The author presents a large diversified basket of favorite names across sectors as where they are positioned for the next few years, but the 30+ tickers default to watch due to the basket size rule.

Author discloses current positioning in CRSP as a Health name, framing the dip as a buying opportunity with a multi-year hold thesis.

Martin Shkreli speculates about a 20-year timeline for CRISPR without expressing a clear bullish or bearish trade opinion.

Accumulate shares as the company successfully transitions to the commercial stage with revenue from approved blood disorder cures while expanding into massive total addressable markets like cardiovascular disease.

In the outro, Becky Quick teases the next episode featuring a child who received a "personalized CRISPR-based gene editing therapy" that likely saved his life. While a teaser, this highlights the shift of CRISPR technology from theoretical research to applied clinical success ("miracles"). Positive real-world outcomes in rare diseases validate the platforms of major gene-editing companies, justifying premium valuations for their pipelines. Long the CRISPR innovators as clinical validation accelerates. Regulatory hurdles; high cost of personalized therapies limiting total addressable market (TAM).

Oz explicitly mentions "CRISPR technology" and states CMS is willing to pay for "drugs... that can cure, not just treat, Sickle Cell Anemia." He cites a cost of "$2 million" but notes it saves the system "$10 million." The primary bear case for gene editing stocks (like CRISPR Therapeutics, Vertex, and bluebird bio) is the fear that insurers/government won't pay the massive upfront price tags. The CMS Administrator confirming they are "banking on these technologies" and will "pay for them when they get there" removes the single biggest overhang for the sector. LONG. Government backing guarantees a market for these high-ticket curative therapies. Clinical trial failures or safety issues with the specific therapies.